住院成人革兰阴性菌血流感染转为口服抗生素治疗
这项回顾性队列研究纳入2019年美国24家医院4581例革兰阴性菌血流感染住院成人,评估静脉转口服抗生素的时机、选择和临床特征。43.0%患者在7天内转为口服,转为口服者免疫抑制、ICU入住、第5天发热或低血压、肾脏替代治疗比例均显著低于维持静脉者,7天内感染源控制比例更高。各医院转口服率差异大(25.8%-65.9%),口服药以氟喹诺酮类为主(62.2%)。作者认为多数患者第5天已达临床稳定,可能存在更早、更频繁转口服的机会。
要点
- 4581例革兰阴性菌血流感染住院成人中,1969例(43.0%)在7天内由静脉转为口服抗生素,转口服中位时间为第5天(IQR 4-6天)。
- 维持静脉治疗者比转口服者更常见免疫抑制(31.9% vs 24.6%;P < .001)、ICU入住(39.5% vs 17.0%;P < .001)、第5天发热或低血压(16.2% vs 2.5%;P < .001)、肾脏替代治疗(10.7% vs 3.2%;P < .001)。
- 转口服者7天内感染源控制比例更高(80.1% vs 70.9%;P < .001);转口服组抗生素总疗程短于静脉组(中位11天[IQR 9-14天] vs 13天[IQR 8-16天];P < .001)。
- 各医院7天内转口服率差异显著,从25.8%(66/256)到65.9%(27/41);4109例(89.7%)在5天内达到临床稳定。
- 口服抗生素以氟喹诺酮类最多(62.2%[1224/1969]),其次为β-内酰胺类(28.3%[558/1969])和甲氧苄啶-磺胺甲噁唑(11.5%[227/1969])。
适用人群与场景
- 2019年1月1日至12月31日在美国24家医院住院的4581例革兰阴性菌血流感染成人患者。
- 排除72小时内死亡的患者;口服治疗组排除第7天后才转换的患者。
研究设计与关键结果
- 研究类型:回顾性队列研究,纳入4581例革兰阴性菌血流感染住院成人(中位年龄67岁[IQR 55-77岁];男性2389例[52.2%]),来自美国24家医院,研究期为2019年1月1日至12月31日。
- 主要结果:1969例(43.0%)接受静脉抗生素的患者在7天内转为口服抗生素;各医院转口服率从25.8%(66/256)到65.9%(27/41)不等。
- 组间比较:维持静脉治疗组 vs 转口服组:免疫抑制833/2612(31.9%) vs 485/1969(24.6%),P < .001;ICU入住1033/2612(39.5%) vs 334/1969(17.0%),P < .001;第5天发热或低血压423/2612(16.2%) vs 49/1969(2.5%),P < .001;肾脏替代治疗280/2612(10.7%) vs 63/1969(3.2%),P < .001;7天内感染源控制1852/2612(70.9%) vs 1577/1969(80.1%),P < .001。
- 临床稳定:4109例(89.7%)在5天内达到临床稳定。
- 感染源控制:3429例(74.9%)在7天内成功控制感染源,口服组感染源控制中位天数为第2天(IQR 1-3天),静脉组为第2天(IQR 1-4天),P < .001。
- 感染来源(口服组):尿路1277/1969(64.9%)、肝胆239/1969(12.1%)、腹腔内194/1969(9.9%)。
- 转口服时机:中位第5天(IQR 4-6天)。
- 抗生素总疗程:口服组中位11天(IQR 9-14天) vs 静脉组中位13天(IQR 8-16天),P < .001。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,由于大多数患者(89.7%)在5天内达到临床稳定,可能存在更早、更频繁转为口服抗生素的机会。
- 转口服实践在医院间差异显著(25.8%-65.9%),提示各机构可评估本机构转口服的时机与选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Management of gram-negative bloodstream infections (GN-BSIs) with oral antibiotics is highly variable.
OBJECTIVE: To examine the transition from intravenous (IV) to oral antibiotics, including selection, timing, and associated clinical and microbial characteristics, among hospitalized patients with GN-BSIs.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted of 4581 hospitalized adults with GN-BSIs at 24 US hospitals between January 1 and December 31, 2019. Patients were excluded if they died within 72 hours. Patients were excluded from the oral therapy group if transition occurred after day 7. Statistical analysis was conducted from July 2022 to October 2023.
EXPOSURES: Administration of antibiotics for GN-BSIs.
MAIN OUTCOMES AND MEASURES: Baseline characteristics and clinical parameters reflecting severity of illness were evaluated in groups receiving oral and IV therapy. The prevalence of transition from IV to oral antibiotics by day 7, median day of transition, sources of infection, and oral antibiotic selection were assessed.
RESULTS: Of a total of 4581 episodes with GN-BSIs (median age, 67 years [IQR, 55-77 years]; 2389 men [52.2%]), 1969 patients (43.0%) receiving IV antibiotics were transitioned to oral antibiotics by day 7. Patients maintained on IV therapy were more likely than those transitioned to oral therapy to be immunosuppressed (833 of 2612 [31.9%] vs 485 of 1969 [24.6%]; P < .001), require intensive care unit admission (1033 of 2612 [39.5%] vs 334 of 1969 [17.0%]; P < .001), have fever or hypotension as of day 5 (423 of 2612 [16.2%] vs 49 of 1969 [2.5%]; P < .001), require kidney replacement therapy (280 of 2612 [10.7%] vs 63 of 1969 [3.2%]; P < .001), and less likely to have source control within 7 days (1852 of 2612 [70.9%] vs 1577 of 1969 [80.1%]; P < .001). Transitioning patients from IV to oral therapy by day 7 was highly variable across hospitals, ranging from 25.8% (66 of 256) to 65.9% (27 of 41). A total of 4109 patients (89.7%) achieved clinical stability within 5 days. For the 3429 episodes (74.9%) with successful source control by day 7, the median day of source control was day 2 (IQR, 1-3 days) for the oral group and day 2 (IQR, 1-4 days) for the IV group (P < .001). Common infection sources among patients administered oral therapy were the urinary tract (1277 of 1969 [64.9%]), hepatobiliary (239 of 1969 [12.1%]), and intra-abdominal (194 of 1969 [9.9%]). The median day of oral transition was 5 (IQR, 4-6 days). Total duration of antibiotic treatment was significantly shorter among the oral group than the IV group (median, 11 days [IQR, 9-14 days] vs median, 13 days [IQR, 8-16 days]; P < .001]. Fluoroquinolones (62.2% [1224 of 1969]), followed by β-lactams (28.3% [558 of 1969]) and trimethoprim-sulfamethoxazole (11.5% [227 of 1969]), were the most commonly prescribed oral antibiotics.
CONCLUSIONS AND RELEVANCE: In this cohort study of 4581 episodes of GN-BSIs, transition to oral antibiotic therapy by day 7 occurred in fewer than half of episodes, principally with fluoroquinolones, although this practice varied significantly between hospitals. There may have been additional opportunities for earlier and more frequent oral antibiotic transitions because most patients demonstrated clinical stability by day 5.
参考来源
- Engers DW, Tamma PD, Fiawoo S, et al. Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections. JAMA Netw Open. 2024. PMID: 38165674. doi:10.1001/jamanetworkopen.2023.49864
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。